Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TERN-701 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| TERN-701 | DRUG | TERN-701 orally QD |
TERN-701 is an investigational small molecule being developed for the treatment of chronic myeloid leukemia (CML) in the chronic phase. It is currently in Phase 2 clinical development and has not been approved by the FDA. The drug is being studied in patients with chronic phase CML.
TERN-701 is a small molecule therapeutic being developed for chronic myeloid leukemia. The specific molecular target of TERN-701 has not been disclosed in the available information. The drug is being evaluated for its safety, tolerability, pharmacokinetics, and efficacy in patients with chronic phase CML.
TERN-701 is being developed by Terns Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol TERN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with chronic phase chronic myeloid leukemia.
TERN-701 is currently in Phase 2 clinical development for chronic phase chronic myeloid leukemia. It has received Orphan Drug and Breakthrough Therapy designations from the FDA. The drug is investigational and has not been approved for commercial use.
TERN-701 is being studied in the CARDINAL trial (NCT06163430), a Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of the drug in participants with chronic myeloid leukemia. The trial is currently recruiting and has a target enrollment of 180 participants.
TERN-701 is the primary name for this investigational drug and no alternative names have been reported. It is being developed by Terns Pharmaceuticals for chronic phase chronic myeloid leukemia and is currently in Phase 2 clinical trials.